What is the market's earnings forecast for Embecta next quarter?

What were the key takeaways from Embecta’s earnings call?

What is Embecta's latest dividend and current dividend yield?

What is Embecta's gross profit margin?

What guidance did Embecta's management provide for the next earnings period?

Did Embecta beat or miss consensus estimates last quarter?

What were the key takeaways from Embecta's earnings call?

What is the revenue and EPS growth rate for Embecta year over year?

- **Strategic Momentum**: Completed 'standup phase', 95% U.S./Canada on Embecta brand, 30+ GLP-1 partners in pipeline.
- **Financial Resilience**: Q1 adj EPS $0.71, $17M free cash flow, net leverage 2.8x; FY26 guidance now skewed to lower end due to U.S. pricing.
- **Growth Drivers**: Intl expansion (EMEA/Latin America up 8.4%), GLP-1 generics launching in 2026, and oral GLP-1s expanding market.

**【CEO Summary Section】**
- **Strategic Progress**: Completed the 'standup phase' with stable core business, transitioning to 'seed growth' phase focusing on portfolio expansion and financial flexibility.
- **Brand Transition**: 95% of U.S. and Canada revenue now under Embecta brand; global rollouts expected by end-2026.
- **GLP-1 Opportunity**: 30+ pharma partners engaged, with 1/3 in contract negotiations; initial generic launches in 2026 (India, Brazil, China) and potential branded partnerships.
- **Q1 2026 Results**: Revenue $261M (-2% YoY), U.S. decline (-7.6%) offset by intl growth (8.4% reported, 4.6% adj). China remains headwind but expected to recover in H2.

**【CFO Financial Commentary】**
- **Q1 Financials**: GAAP net income $44.1M, adj EPS $0.71 (vs $0.65 prior). Free cash flow $17M, debt reduced by $38M, net leverage 2.8x.
- **Guidance Update**: Closer to lower end of FY26 guidance ($1.71-1.93B revenue, 29-30% adj margin, $2.80-3.00 adj EPS) due to U.S. pricing headwinds.
- **Cash Flow Focus**: $180-200M free cash flow expected, supporting debt repayment and strategic initiatives.

**【Q&A Highlights】**
- **U.S. Dynamics**: Pricing mix and channel contraction drove Q1 decline; intl strength (EMEA/Latin America) offsets China headwinds.
- **China Recovery**: Q1 performance in line with expectations; H2 recovery expected amid geopolitical stabilization.
- **GLP-1 Outlook**: $100M+ opportunity intact; oral GLP-1s expand market, injectables retain efficacy advantage.
- **New Products**: Pen injector project in early stages; potential TAM to be defined as partnerships evolve.

Embecta Corp. (EMBC) Q1 2026 Earnings Call Transcript

- **Revenue decline**: Fiscal 2025 revenue down 7.7% YoY to $1.07B, driven by U.S. and China challenges.
- **GLP-1 growth opportunity**: 30+ partnerships targeting $100M+ by 2033, with 2026 launches in key markets.
- **Financial discipline**: 2.9x leverage, $182M free cash flow, and $184M debt reduction in 2025.
- **Key risks**: 2% cannula cost increase, China market competition, and U.S. pharmacy closures.
- **2026 outlook**: Flat to -2% revenue growth, 29-30% adjusted operating margin, and $180-200M free cash flow.

**【CEO Summary Section】**
- Fiscal 2025 revenue declined 7.7% YoY to $1.07 billion, driven by U.S. market challenges (15.2% decline) and China headwinds (3.1% constant currency decline). 
- Completed restructuring with $182M free cash flow and $184M debt reduction, lowering leverage to 2.9x.
- Advanced GLP-1 partnerships with 30+ generic drug manufacturers, targeting $100M+ annual revenue by 2033. 
- Pen needle revenue down 7.1% YoY ($784M) due to transitory factors, while syringes (+1.7%) and safety products (+6.3%) showed growth.
- 2026 guidance: Flat to -2% revenue growth (as-reported $1.07-1.09B), adjusted operating margin 29-30%, and $180-200M free cash flow.

**【CFO Financial Commentary】**
- Q4 2025 GAAP net income $26.4M ($0.45 EPS), adjusted net income $29.4M ($0.50 EPS). Full year adjusted EBITDA $415.3M (38.5% margin).
- 2026 financial targets: Adjusted EPS $2.80-3.00, free cash flow $180-200M, and $150M debt repayment.
- Key risks: 2% cannula cost increase, China market competition, and U.S. pharmacy closures.

**【Q&A Key Highlights】**
- **GLP-1 Progress**: 30+ partnerships, $10M+ orders in 2025, targeting 2026 launches in Brazil, India, Canada.
- **China Challenges**: 4% constant currency decline, but stabilizing with price-competitive products.
- **Cannula Costs**: 2% increase in 2026, seeking alternative suppliers to mitigate BD sole-source risk.
- **M&A Strategy**: Open to tuck-in acquisitions as leverage improves below 3x.
- **Patch Pump Sale**: $10M IP sale post-year-end, no impact on 2026 guidance.


Embecta Corp. (EMBC) Q4 2025 Earnings Call Transcript

- **Revenue Surges to Record $295.5M**: U.S. growth 11.6% YoY, driven by pricing adjustments and distributor orders. International markets offset China decline with Latin America/Asia gains.
- **Debt Reduction Exceeds Target**: $112M paid YTD vs. $110M goal, with $150M FY25 target. Free cash flow $81M in Q3, up 140% YoY.
- **GLP-1 Pen Needle Expansion**: 30+ pharma partnerships could generate $100M+ annual revenue by 2033. Q4 China risks weigh on near-term outlook.
- **Margins Strengthen**: Adjusted EBITDA margin 44.3%, up 800bps YoY. Raised adj. EPS to $2.90-2.95, +12.5% at midpoint.

**【CEO Summary Section】**
- **Revenue Record High**: Q3 revenue reached $295.5 million, up 8.4% YoY, driven by U.S. pricing and volume growth. U.S. revenue grew 11.6%, while international revenue rose 5.0%.
- **Brand Transition Completion**: 100% of revenue now flows through Embecta systems post-ERP implementation. North America brand transition >90% complete, with international rollouts planned for 2026.
- **GLP-1 Pen Needle Expansion**: Collaborating with 30+ pharma companies for co-packaging, with potential 2026 commercialization. Retail small packs could add $100M+ annual revenue by 2033.
- **Cost Savings**: Restructuring achieved $7-8M Q3 savings, targeting $15M annualized. Debt reduced by $112M YTD, exceeding $110M FY25 target.

**【CFO Financial Commentary】**
- **Profitability**: GAAP net income $45.5M ($0.78 EPS), up 212% YoY. Adjusted EBITDA $131M (44.3% margin), up 32% YoY.
- **Cash Flow**: Generated $81M free cash flow (incl. $26M factoring benefit), with $234M cash balance. Net leverage 3.2x vs. 4.75x covenant.
- **Updated Guidance**: Narrowed FY25 as-reported revenue to $1.078-1.085B (-3.4% to -4.0% YoY). Raised adj. EPS to $2.90-2.95 (prev. $2.70-2.90).

**【Q&A Highlights】**
- **Q4 Outlook**: Q4 revenue expected to drop to $265M midpoint, driven by reversing U.S. distributor orders and rebate benefits. Gross margin may decline 400bps due to lower revenue and P&I costs.
- **China Risks**: Q4 China revenue expected to decline due to geopolitical tensions and local brand preference. Long-term growth potential remains despite short-term headwinds.
- **Capital Allocation**: Debt paydown remains priority, with $150M FY25 target. Share buybacks not planned amid focus on growth investments.
- **GLP-1 Syringe Impact**: Syringes technically usable for GLP-1 but not marketed for it. Pen needles for generics seen as larger opportunity than compounding syringe demand.

Embecta Corp. (EMBC) Q3 2025 Earnings Call Transcript

- **Revenue Beat**: Q2 revenue $259M (+9.8% YoY as-reported), beating $250-255M guidance. US volumes down 8.4% due to price increase timing, but international syringes up 1.7%.
- **Margin Expansion**: Adjusted operating margin 31.4% (vs 26.1% Y/Y), driven by $39M R&D savings from pump program termination.
- **Debt Reduction**: $27M Q2 debt paydown, on track for $110M FY2025 reduction. Net leverage 3.7x vs 4.75x covenant.
- **Tariff Risk**: 25bps FY2025 gross margin headwind, potential $8-9M FY2026 impact if tariffs remain.
- **Growth Catalysts**: GLP-1 co-packaging with generics, retail pen needle kits, 73% contract manufacturing growth.


**【CEO Strategic Priorities】**
- **Core Business Strengthening**: Global brand transition underway in US/Canada, targeting substantial completion by end of FY2025. Pen needle co-packaging with generic GLP-1 drugs initiated, with purchase orders received from multiple generic manufacturers.
- **Product Portfolio Expansion**: Syringe revenue grew 1.7% Y/Y (driven by Latin America/Asia), safety products up 4.2% due to competitor exit. Contract manufacturing surged 73%.
- **Financial Flexibility**: $27M debt reduction in Q2, total FY2025 debt target of $110M. Restructuring plan to save $7-8M in H2, with $4-5M pre-tax charges.

**【CFO Financial Highlights】**
- **Q2 Results**: Revenue $259M (beat guidance), GAAP net income $23.5M, Non-GAAP EPS $0.70. Adjusted EBITDA $97.1M (37.5% margin vs 31.6% Y/Y).
- **Gross Margin**: 63.7% (down 100bps Y/Y due to lower volumes, tariffs). Operating margin 31.4% (up 530bps Y/Y from cost cuts).
- **Tariff Impact**: FY2025 gross margin headwind of 25bps, potential $8-9M annualized impact in FY2026 if tariffs persist.

**【Q&A Key Takeaways】**
- **Demand Dynamics**: US pen needle market stable, syringes strong in Latin America/Asia. Retail pharmacy closures causing temporary distributor cautiousness.
- **Tariff Mitigation**: $3M incremental FY2025 cost from US-China tariffs, exemptions for medical devices limit impact.
- **Efficiency Plan**: $7-8M H2 savings (SG&A cuts), targeting $15M+ annualized in FY2026.
- **GLP-1 Expansion**: Co-packaging with generics progressing, retail pen needle kits launching Q3.


Embecta (EMBC)-9 May 25-2025 Q2 Earnings call transcript

- **Revenue Resilience**: Q1 2025 revenue ($262M) exceeded internal expectations, driven by timing benefits from price increases and distributor orders. FY2025 guidance reflects 1-2.5% constant currency decline.
- **Strategic Expansion**: Exploring partnerships to leverage global distribution for third-party products, with 10+ GLP-1 co-packaging discussions advancing.
- **Debt Reduction Focus**: $32M Q1 debt repayment; targeting $110M FY2025 reduction to enhance financial flexibility and net leverage below 3x by end of year.
- **Operational Efficiency**: Adjusted operating margin raised to 29.5-30.5% due to cost savings ($0.10 EPS headwind offset).

**【CEO Strategic Priorities】**
- **Core Business Strengthening**: Executing brand transition to enhance global identity while maintaining customer trust. Expanding leadership in insulin injection devices.
- **Product Portfolio Expansion**: Exploring partnerships to manufacture products for third-party commercial channels and leverage global distribution networks. 
- **Financial Flexibility**: Discontinued insulin patch pump program; $110M debt reduction target for FY2025. Free cash flow expected to reduce debt significantly over next few years.

**【Q1 2025 Financial Highlights】**
- **Revenue**: $262M (5.6% YoY decline, 4.8% constant currency). US revenue $141.7M (-4.6% YoY), driven by ERP implementation timing and distributor rebalancing.
- **Product Performance**: Pen needles down 8.5%, syringes down 4.2%, safety products up 11.3%, contract manufacturing up 153%.
- **Debt Reduction**: $32M Term Loan B repayment Q1, on track for $110M FY2025.

**【CFO Financial Review】**
- **Gross Margin**: 60% (GAAP) / 62.7% (non-GAAP), down due to lower revenue and inventory adjustments, offset by price increases.
- **Operating Income**: $80.5M (30.7% margin), up from $77.5M (27.9%) YoY, driven by R&D savings and cost reductions.
- **Net Income**: $38.3M (EPS $0.65), up 8.5% YoY. Adjusted EBITDA $97.3M (37.2% margin).
- **Balance Sheet**: $217M cash, net leverage 3.7x (covenant limit 4.75x).

**【Updated FY2025 Guidance】**
- **Revenue**: Constant currency down 1-2.5%, as-reported down 2.8-4.3% due to FX headwinds.
- **Margins**: Gross margin 63.25-64.25%, operating margin 29.5-30.5%, EBITDA margin 36-37%.
- **EPS**: $2.70-$2.90, absorbing $0.10 FX headwind through cost savings.

**【Q&A Key Takeaways】**
- **GLP-1 Pen Needle Expansion**: Co-packaging discussions with 10+ generic GLP-1 entrants progressing. Germany adoption to be monitored for out-of-pocket prescriptions.
- **M&A Strategy**: Long-term focus on incremental revenue opportunities ($10-15M/year to drive 1% growth). Near-term priority on debt reduction to 3x net leverage by FY2025.
- **Long-Term Margin Outlook**: Analyst Day (May 2025) to detail margin progression balancing new product opportunities with core business efficiency.

Actual	1.38	1.07	-0.3	0.96	0.75	0.69	0.59	0.61	0.67	0.74	0.45	0.65	0.7	1.12	0.5	0.71
Forecast		0.87	0.5967	0.51	0.4833	0.46	0.3975	0.455	0.4	0.464	0.362	0.4933	0.528	0.775	0.455	0.671
Surprise	0.00%	+22.99%	-150.28%	+88.24%	+55.18%	+50.00%	+48.43%	+34.07%	+67.50%	+59.48%	+24.31%	+31.77%	+32.58%	+44.52%	+9.89%	+5.81%

EMBC

EMBC fundamentals

EMBC Q1 2026 Earnings

Earnings Call

You can ask Aime

EMBC

EMBC fundamentals

EMBC Q1 2026 Earnings

Earnings Call

EMBC Earnings Call Summary for Q1/20268:00 AM on Feb 5, 2026

EMBC Earnings Call Summary for Q4/20258:00 AM on Nov 25, 2025

EMBC Earnings Call Summary for Q3/20258:00 AM on Aug 8, 2025

EMBC Earnings Call Summary for Q2/20258:00 AM on May 9, 2025

EMBC Earnings Call Summary for Q1/20258:00 AM on Feb 6, 2025

You can ask Aime